SU5416 (Semaxanib): Selective VEGFR2 Inhibitor for Cancer and Immune Modulation

Executive Summary: SU5416 (Semaxanib) is a highly selective small molecule inhibitor of the vascular endothelial growth factor receptor 2 (VEGFR2; Flk-1/KDR), suppressing VEGF-induced phosphorylation and endothelial cell proliferation at an IC50 of 1.23 μM in vitro (APExBIO). It exhibits over 1000-fold selectivity for VEGF-driven versus FGF-driven mitogenesis, minimizing off-target effects (APExBIO). SU5416 also acts as an aryl hydrocarbon receptor (AHR) agonist, inducing indoleamine 2,3-dioxygenase (IDO) and promoting regulatory T cell differentiation (Amyloid-A-Protein-Fragment-Homo-Sapiens.com). In preclinical rodent models, a single dose of 20 mg/kg SU5416 robustly induces pulmonary hypertension under hypoxic conditions, validating its role in vascular and immune research (Zhang et al. 2024). The compound is insoluble in ethanol and water but readily dissolves in DMSO (≥11.9 mg/mL), facilitating experimental use (APExBIO).

Biological Rationale

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is critical for tumor growth, metastasis, and chronic inflammation. The VEGF signaling pathway, primarily mediated via VEGFR2 (Flk-1/KDR), is a central regulator of angiogenic processes in physiological and pathological contexts. Overexpression of VEGF and activation of VEGFR2 are frequently observed in solid tumors and contribute to tumor vascularization, growth, and resistance to therapy (Zhang et al. 2024). Targeted inhibition of VEGFR2 is a validated strategy for suppressing pathological angiogenesis and has translational relevance in oncology, autoimmune disease, and transplantation research.

Mechanism of Action of SU5416 (Semaxanib)

SU5416 (Semaxanib) is a synthetic indolinone derivative with the chemical name (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one (C₁₅H₁₄N₂O, MW 238.28). It selectively inhibits the Flk-1/KDR (VEGFR2) receptor tyrosine kinase domain, blocking VEGF-mediated autophosphorylation and downstream mitogenic signaling in endothelial cells (APExBIO). SU5416 shows an IC50 of 1.23 μM for VEGFR2 in cell-based phosphorylation assays and displays >1000-fold selectivity for VEGF versus FGF-driven mitogenesis, indicating minimal cross-reactivity with other receptor tyrosine kinases.
In addition to VEGFR2 inhibition, SU5416 is a potent agonist of the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor modulating immune responses. AHR activation by SU5416 induces expression of indoleamine 2,3-dioxygenase (IDO), an enzyme that catalyzes tryptophan catabolism and promotes regulatory T cell (Treg) differentiation, contributing to immune tolerance (Amyloid-A-Protein-Fragment-Homo-Sapiens.com).

Evidence & Benchmarks

• SU5416 inhibits VEGF-induced proliferation of human endothelial cells with an IC50 of 1.23 μM (APExBIO, https://www.apexbt.com/su5416.html).
• In vivo, SU5416 administered at 3–25 mg/kg/day significantly suppresses tumor growth in murine xenograft models without observed mortality (APExBIO, https://www.apexbt.com/su5416.html).
• SU5416 induces pulmonary hypertension in rodents when administered as a single 20 mg/kg injection followed by 3 weeks of hypoxia, serving as a robust preclinical model for pulmonary vascular disease (Zhang et al. 2024, https://doi.org/10.1002/pul2.12358).
• SU5416 exhibits >1000-fold selectivity for VEGF-driven mitogenesis compared to FGF-driven pathways, as demonstrated in cell proliferation assays (APExBIO, https://www.apexbt.com/su5416.html).
• As an AHR agonist, SU5416 induces IDO expression and increases regulatory T cell differentiation in immune modulation assays (https://amyloid-a-protein-fragment-homo-sapiens.com).

Applications, Limits & Misconceptions

SU5416 (Semaxanib) is widely used in research models of angiogenesis, tumor growth, pulmonary hypertension, and immune regulation. Its dual mechanism allows for hypothesis-driven studies dissecting the interplay between angiogenic and immune pathways. For example, in pulmonary hypertension models, SU5416 is a gold-standard agent for inducing severe PH when combined with hypoxia, as validated by VO₂ max and echocardiographic endpoints (Zhang et al. 2024). In cancer research, SU5416 enables investigation of VEGF pathway dependencies and resistance mechanisms in solid tumors.

For further exploration of SU5416’s strategic value in translational research, readers may consult this mechanistic overview, which situates SU5416’s dual action within the competitive research landscape; the present article extends these insights by providing specific experimental benchmarks and pitfalls.

Common Pitfalls or Misconceptions

• Not a clinical or diagnostic agent: SU5416 is for research use only and is not approved for human therapeutic use (APExBIO).
• Solubility limitations: SU5416 is insoluble in ethanol and water; improper solvent selection can lead to precipitation and loss of activity.
• Degradation risk: Stock solutions in DMSO should be stored below -20°C and used promptly to avoid hydrolysis and degradation (APExBIO).
• VEGF pathway-specific action: SU5416 does not inhibit non-VEGF-driven angiogenesis, such as that mediated exclusively by FGF or PDGF (APExBIO).
• Species- and strain-dependent effects: Certain rodent strains may show differential sensitivity to SU5416-induced pulmonary hypertension (Zhang et al. 2024).

Workflow Integration & Parameters

SU5416 (SKU A3847) from APExBIO is supplied as a solid and should be dissolved in DMSO at concentrations of at least 11.9 mg/mL. Working solutions should be freshly prepared and diluted into compatible aqueous buffers immediately prior to use. Typical experimental concentrations range from 0.01 to 100 μM in cell-based assays, while in vivo studies employ dosing between 3 and 25 mg/kg/day for tumor models or a single 20 mg/kg dose for pulmonary hypertension induction (Zhang et al. 2024). Example workflows, troubleshooting guides, and scenario-driven recommendations are available in this protocol-focused article, which this article updates with validated quantitative benchmarks and current storage guidelines.

For scenario-driven data interpretation in angiogenesis and immune modulation assays, see this resource; the current review extends those insights by clarifying selectivity and cross-pathway effects.

Conclusion & Outlook

SU5416 (Semaxanib) is a reference-standard selective VEGFR2 tyrosine kinase inhibitor and AHR agonist, enabling robust and reproducible inhibition of angiogenesis and targeted immune modulation in preclinical models. Its high selectivity, validated in both in vitro and in vivo systems, makes it a valuable tool for hypothesis-driven research in cancer, pulmonary hypertension, autoimmunity, and transplant tolerance. When using SU5416, researchers should ensure optimal dissolution, storage, and dosing to maximize reproducibility. As new mechanistic insights and model refinements emerge, SU5416’s role as a benchmark compound in vascular and immunological studies is expected to remain central. For additional product details and ordering information, visit the SU5416 (Semaxanib) product page at APExBIO.